nach oben

Drugs & Aging

Erschienen in:

01.10.2001 | Review Article

Epidemiology of Breast Cancer in Older Women

Implications for Future Healthcare

verfasst von: Anthony J. Alberg, Sonia Singh

Erschienen in: Drugs & Aging | Ausgabe 10/2001

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer in elderly women is already a significant public health problem. Elderly women have a 6-fold higher breast cancer incidence rate and 8-fold higher mortality rate compared with non-elderly women. Because of demographic trends, the number of elderly women diagnosed with breast cancer is likely to increase substantially in the coming decades. Specifically, if incidence rates remain constant, we project a 72% increase in the number of elderly women in the US diagnosed with breast cancer by 2025, an increase from approximately 89 500 in 1998 to almost 154 000 in 2025. If this projection holds true, the sheer magnitude of the increase in patients has profound implications for the delivery of medical care. Considerable planning is needed to ensure that the infrastructure is in place to effectively treat these patients. The burgeoning number of elderly patients with breast cancer accentuates the need for more definitive evidence concerning preventing and treating breast cancer in the elderly.

Treatment patterns for elderly patients with breast cancer have been shown to differ from those for non-elderly patients, but the evidence base for differentiating treatment plans by age is deficient. For example, information is needed to tease apart the relative importance of age per se compared with important age-related factors, such as comorbidity. Patient care will benefit from an interdisciplinary team approach that includes oncologists, geriatricians, surgeons, radiation oncologists, nurses and social workers.

The continued increase in life expectancy necessitates well-crafted strategies for the primary and secondary prevention of breast cancer. Carefully addressing the priorities for breast cancer prevention and control in the elderly during the first portion of the century may reap substantial dividends by the end of the century.

National Center for Health Statistics. Health, United States. Health and aging chartbook. Hyattsville (MA): National Center for Health Statistics, 1999

American Cancer Society. Cancer facts and figures 2000. Atlanta (GA): American Cancer Society, 2000

Cohen S. Psychosocial models of the role of social support in the etiology of physical disease. Health Psychol 1988; 7: 269–97PubMedCrossRef

House JS, Landis KR, Umberson D. Social relationships and health. Science 1988; 241: 540–5PubMedCrossRef

Balducci L, Extermann M. Management of the frail person with advanced cancer. Crit Rev Oncol Hematol 2000; 33: 143–8PubMedCrossRef

Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1997. Bethesda (MD): National Cancer Institute, 2000

Ries LAG, Kosary LG, Hankey BF, et al. SEER cancer statistics review, 1973-1996. Bethesda (MD): National Cancer Institute, 1999. Report No.: NIH Pub. 99-2789

Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000; 92: 550–6PubMedCrossRef

US Bureau of the Census. Current population reports, Special studies, P23-190, 65+ in the United States. Washington, DC: US Bureau of the Census, 1996

10.

Hollmann FW, Mulder TJ, Kalian J. Methodology and assumptions for the projections of the United States: 1999 to 2100. Population division working paper number 38. Washington, DC: US Census Bureau, 2000

11.

Projections of the total resident population by 5-year age groups, and sex with special age categories: Middle series, 1999-2100. Washington, DC: US Census Bureau, 2000. Available from URL: http://www.census.gov/population/www/projections/natsum-T3.html [Accessed 2001 Sep 4]

12.

Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997; 80: 1273–83PubMedCrossRef

13.

Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. Amsterdam: Harwood Academic Publishers, 1998

14.

Estimated US Cancer Prevalence Counts. National Cancer Institute. Statistical Research Applications Branch [online]. Available from: URL: http://srab.cancer.gov/Prevalence/ [Accessed 2001 Sep 4]

15.

Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 1997; 8: 764–70PubMedCrossRef

16.

Evans HS, Lewis CM, Robinson D, et al. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 2001; 84: 435–40PubMedCrossRef

17.

Horn-Ross PL. Multiple primary cancers involving the breast. Epidemiol Rev 1993; 15: 169–76PubMed

18.

Yancik R, Ries LG, Yates JW Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 1989; 63: 976–81PubMedCrossRef

19.

Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159–70PubMedCrossRef

20.

Yancik R, Wesley MN, Ries LAG, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885–92PubMedCrossRef

21.

Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87: 417–26PubMedCrossRef

22.

Newschaffer CJ, Penberthy L, Desch CE, et al. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996; 156: 85–90PubMedCrossRef

23.

West DW, Satariano WA, Ragland DR, et al. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 1996; 6: 413–9PubMedCrossRef

24.

Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104–10PubMed

25.

Exterman M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18: 1709–17

26.

Bernabei R, Venturiero V, Tarsitani P, et al. The comprehensive geriatric assessment: when, where, how. Crit Rev Oncol Hematol 2000; 33: 45–56PubMedCrossRef

27.

Mandelblatt JS, Wheat ME, Monane M, et al. Breast cancer screening for elderly women with and without comorbid conditions. A decision analysis model. Ann Intern Med 1992; 116: 722–30PubMed

28.

Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000; 14: 63–77PubMedCrossRef

29.

Yancik R. Integration of aging and cancer research in geriatric medicine. J Gerontol ABiol Sci Med Sci 1997; 52(6) Suppl.: M329–32CrossRef

30.

Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic prospectives. Hematol Oncol Clin North Am 2000; 14: 17–23PubMedCrossRef

31.

Silliman RA, Guadagnoli E, Weitberg AB, et al. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 1989; 44(2) Suppl.: M46–50PubMedCrossRef

32.

Lash TL, Silliman RA, Guadagnoli E, et al. The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer 2000; 89: 1739–47PubMedCrossRef

33.

Bergman L, Kluck HM, van Leeuwen FE, et al. The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: a population-based study. Eur J Cancer 1992; 28A(8–9) Suppl.: 1475–80PubMedCrossRef

34.

de Rijke JM, Schouten LJ, Schouten HC, et al. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands. Ann Oncol 1996; 7: 677–85PubMedCrossRef

35.

Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 2000; 89: 561–73PubMedCrossRef

36.

Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 2001; 19: 1455–61PubMed

37.

Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer 1993; 72: 594–601PubMedCrossRef

38.

Zachariah B, Balducci L. Radiation therapy of the older patient. Hematol Oncol Clin North Am 2000; 14: 131–67PubMedCrossRef

39.

Overgaard M, Jensen M-B, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641–8PubMedCrossRef

40.

van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210–8PubMedCrossRef

41.

Schagen SB, van Dam FS AM, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640–50PubMedCrossRef

42.

Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695–701PubMed

43.

Goodwin JS, Hunt WC, Humble CG, et al. Cancer treatment protocols. Who gets chosen? Arch Intern Med 1988; 148: 2258–60PubMedCrossRef

44.

Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74: 2208–14PubMedCrossRef

45.

Kimmick GG, Balducci L. Breast cancer and aging. Clinical interactions. Hematol Oncol Clin North Am 2000; 14(1): 213–34PubMedCrossRef

46.

Bernstein L, Henderson BE, Hanisch R, et al. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86: 1403–8PubMedCrossRef

47.

D’Avanzo B, Nanni O, La Vecchia C, et al. Physical activity and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5: 155–60PubMed

48.

Friedenreich CM, Rohan TE. A review of physical activity and breast cancer. Epidemiology 1995; 6: 311–7PubMedCrossRef

49.

Levi F, Pasche C, Lucchini F, et al. Occupational and leisure time physical activity and the risk of breast cancer. Eur J Cancer 1999; 35: 775–8PubMedCrossRef

50.

Thune I, Brenn T, Lund E, et al. Physical activity and the risk of breast cancer. N Engl J Med 1997; 336: 1269–75PubMedCrossRef

51.

Morabia A, Bernstein M, Heritier S, et al. Relation of breast cancer with passive and active exposure to tobacco smoke. Am J Epidemiol 1996; 143: 918–28PubMedCrossRef

52.

Lash TL, Aschengrau A. Active and passive cigarette smoking and the occurrence of breast cancer. Am J Epidemiol 1999; 149: 5–12PubMedCrossRef

53.

Johnson KC, Hu J, Mao Y. Passive and active smoking and breast cancer risk in Canada, 1994–97. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control 2000; 11: 211–21PubMedCrossRef

54.

Ambrosone CB, Freudenheim JL, Graham S, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996; 276: 1494–501PubMedCrossRef

55.

Schatzkin A, Longnecker MR Alcohol and breast cancer. Where are we now and where do we go from here? Cancer 1994; 74: 1101–10PubMedCrossRef

56.

Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997; 337: 1705–14PubMedCrossRef

57.

Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371–88PubMedCrossRef

58.

Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93–7PubMed

59.

Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101PubMed

60.

Brown PH, Lippman SM. Chemoprevention of breast cancer. Breast Cancer Res Treat 2000; 62: 1–17PubMedCrossRef

61.

Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829–46PubMedCrossRef

62.

Stewart HJ, Prescott RJ, Forrest PM. Scottish Adjuvant Tamoxifen Trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456–62PubMedCrossRef

63.

Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189–97PubMedCrossRef

64.

Chlebowski RT, Collyar DE, Somerfield MR, et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999; 17: 1939–55PubMed

65.

Screening for Breast Cancer (PDQ) Screening/Detection -Health Professionals [online]. Available from: URL: http://cancernet.nci.nih.gov/pdq/pdq_screening.shtml [Accessed 2001 Sep 4]

66.

Feig SA. Age-related accuracy of screening mammography: how should it be measured? Radiology 2000; 214: 633–40PubMed

67.

Kerlikowske K, Grady D, Barclay J, et al. Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA 1996; 276: 39–43PubMedCrossRef

68.

van Gils CH, Otten JD, Verbeek AL, et al. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, the Netherlands. J Epidemiol Community Health 1998; 52: 267–71PubMedCrossRef

69.

Litherland JC, Stallard S, Hole D, et al. The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 1999; 54: 285–8PubMedCrossRef

70.

Kerlikowske K, Grady D, Barclay J, et al. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996; 276: 33–8PubMedCrossRef

71.

Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338: 1089–96PubMedCrossRef

72.

Welch HG, Fisher ES. Diagnostic testing following screening mammography in the elderly. J Natl Cancer Inst 1998; 90: 1389–92PubMedCrossRef

73.

Smith-Bindman R, Kerlikowske K. Is there a downside to elderly women undergoing screening mammography? J Natl Cancer Inst 1998; 90: 1322–3PubMedCrossRef

74.

Kerlikowske K, Salzmann P, Phillips KA, et al. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA 1999; 282: 2156–63PubMedCrossRef

75.

Schapira MM, McAuliffe TL, Nattinger AB. Underutilization of mammography in older breast cancer survivors. Med Care 2000; 38: 281–9PubMedCrossRef

76.

Lash TL, Silliman RA. Medical surveillance after breast cancer diagnosis. Med Care 2001; 39: 945–55PubMedCrossRef

77.

Burack RC, Gurney JG, McDaniel AM. Health status and mammography use among older women. J Gen Intern Med 1998; 13: 366–72PubMedCrossRef

78.

Mandelblatt JS, Yabroff KR. Breast and cervical cancer screening for older women: recommendations and challenges for the 21st century. J Am Med Womens Assoc 2000; 55: 210–5PubMed

79.

May DS, Kiefe CI, Funkhouser E, et al. Compliance with mammography guidelines: physician recommendation and patient adherence. Prev Med 1999; 28: 386–94PubMedCrossRef

80.

Edwards NI, Jones DA. Uptake of breast cancer screening in older women. Age Ageing 2000; 29: 131–5PubMedCrossRef

81.

Gulitz E, Bustillo-Hernandez M, Kent EB. Missed cancer screening opportunities among older women: a review. Cancer Pract 1998 Sep–Oct; 6(5): 289–95PubMedCrossRef

82.

Tambor ES, Rimer BK, Strigo TS. Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am J Med Genet 1997; 68: 43–9PubMedCrossRef

83.

Durfy SJ, Bowen DJ, McTiernan A, et al. Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev 1999; 8: 369–75PubMed

84.

Collaborative group on hormonal factors in breast cancer. Breast cancer and hormonal contraceptives: collaborative re-analysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiologic studies. Lancet 1996; 347: 1713–27CrossRef

Titel: Epidemiology of Breast Cancer in Older Women
Implications for Future Healthcare
verfasst von: Anthony J. Alberg
Sonia Singh
Publikationsdatum: 01.10.2001
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 10/2001
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200118100-00005

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2001

Fetal Tissue Transplantation for Patients with Parkinson’s Disease

Current Management Strategies for Hepatitis B in the Elderly

Cisplatin/Epinephrine Injectable Gel